Key Documents

View All Documentation

SML1312

Mubritinib

Name: Mubritinib
Brand: SIGMA

≥98% (HPLC)

Synonym(s):

(E)-4-((4-(4-(1H-1,2,3-triazol-1-yl)butyl)phenoxy)methyl)-2-(4-(trifluoromethyl)styryl)oxazole, 1-[4-[4-[[2-[(1E)-2-[4-(Trifluoromethyl)phenyl]ethenyl]-4-oxazolyl]methoxy]phenyl]butyl]-1H-1,2,3-triazole, CID 6444692, TAK 165, TAK-165

Select a Size

Change View

About This Item

Empirical Formula (Hill Notation):

C₂₅H₂₃F₃N₄O₂

CAS Number:

366017-09-6

Molecular Weight:

468.47

NACRES:

NA.77

PubChem Substance ID:

329825777

UNSPSC Code:

12352200

MDL number:

MFCD09954135

Assay:

≥98% (HPLC)

Form:

powder

Quality level:

100

Technical Service

Need help? Our team of experienced scientists is here for you.

Let Us Assist

Properties

Quality Level

100

assay

≥98% (HPLC)

form

powder

color

white to beige

solubility

DMSO: 5 mg/mL, clear (warmed)

storage temp.

2-8°C

SMILES string

FC(F)(F)C1=CC=C(/C=C/C2=NC(COC3=CC=C(C=C3)CCCCN4C=CN=N4)=CO2)C=C1

InChI

1S/C25H23F3N4O2/c26-25(27,28)21-9-4-20(5-10-21)8-13-24-30-22(18-34-24)17-33-23-11-6-19(7-12-23)3-1-2-15-32-16-14-29-31-32/h4-14,16,18H,1-3,15,17H2/b13-8+

InChI key

ZTFBIUXIQYRUNT-MDWZMJQESA-N

Gene Information

human ... ERBB2(2064)

Description

Biochem/physiol Actions

Mubritinib (TAK-165) is a potent and selective inhibitor of ErbB-2 (HER2).

Mubritinib (TAK-165) is a potent and selective inhibitor of the human epidermal growth factor receptor 2 ErbB (HER2) tyrosine kinase. Mubritinib potently inhibits proliferation of cancer cell lines over- expressing ErbB2.

Storage Class

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Regulatory Information

新产品

This item has

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Development of actionable targets of multi-kinase inhibitors (AToMI) screening platform to dissect kinase targets of staurosporines in glioblastoma cells.

Oxana V Denisova et al.

Scientific reports, 12(1), 13796-13796 (2022-08-14)

Therapeutic resistance to kinase inhibitors constitutes a major unresolved clinical challenge in cancer and especially in glioblastoma. Multi-kinase inhibitors may be used for simultaneous targeting of multiple target kinases and thereby potentially overcome kinase inhibitor resistance. However, in most cases

Cathelicidin-mediated lipopolysaccharide signaling via intracellular TLR4 in colonic epithelial cells evokes CXCL8 production.

Ravi Holani et al.

Gut microbes, 12(1), 1785802-1785802 (2020-07-14)

We hypothesized that the antimicrobial peptide cathelicidin has a physiological role in regulating gut inflammatory homeostasis. We determined that cathelicidin synergizes with LPS to facilitate its internalization and signaling via endosomic TLR4 in colonic epithelium, evoking synthesis of the human

Global Trade Item Number

SKU	GTIN
SML1312-25MG	04061832963815
SML1312-5MG	04061832963822

Key Documents

Mubritinib

≥98% (HPLC)

Select a Size

About This Item

Quality Level

assay

form

color

solubility

storage temp.

SMILES string

InChI

InChI key

Gene Information

Biochem/physiol Actions

Safety Information

Storage Class

wgk

flash_point_f

flash_point_c

Regulatory Information

Documentation

Certificates of Analysis (COA)

Already Own This Product?

Peer Reviewed Papers

Global Trade Item Number